TY - JOUR
T1 - Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer
T2 - a multicenter retrospective study
AU - Uda, Sayaka
AU - Yamada, Tadaaki
AU - Yoshimura, Akihiro
AU - Goto, Yasuhiro
AU - Yoshimine, Kohei
AU - Nakamura, Yoichi
AU - Shiotsu, Shinsuke
AU - Yokoi, Takashi
AU - Tamiya, Nobuyo
AU - Kimura, Hideharu
AU - Chihara, Yusuke
AU - Umeda, Yukihiro
AU - Izumi, Miiru
AU - Takeda, Takayuki
AU - Yamada, Takahiro
AU - Hibino, Makoto
AU - Hiranuma, Osamu
AU - Ito, Kazuhiro
AU - Okada, Asuka
AU - Osugi, Shuji
AU - Takemura, Yoshizumi
AU - Ishii, Hiroshi
AU - Chibana, Kenji
AU - Hasegawa, Isao
AU - Morimoto, Yoshie
AU - Iwasaku, Masahiro
AU - Tokuda, Shinsaku
AU - Takayama, Koichi
N1 - Funding Information:
We would like to thank the patients, their families, and all investigators involved in this study. This work was supported by Editage (www.editage.com) for English language editing. Funding: None.
Funding Information:
Peer Review File: Available at https://tlcr.amegroups.com/ article/view/10.21037/tlcr-22-160/prf Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups. com/article/view/10.21037/tlcr-22-160/coif). Tadaaki Yamada serves as an unpaid editorial board member of Translational Lung Cancer Research from September 2019 to September 2023. Tadaaki Yamada received commercial research grants from Pfizer, Ono Pharmaceutical, Janssen Pharmaceutical K.K., and Takeda Pharmaceutical Company Limited and personal fees from Eli Lilly. AO received personal fees from Chugai-Roche, AstraZeneca, Boehringer Ingelheim, and Bristol Myers Squibb. KT received research grants from Chugai-Roche and Ono Pharmaceutical and individual fees from AstraZeneca, Chugai-Roche, MSD-Merck, Eli Lilly Boehringer Ingelheim, and Daiichi Sankyo. The other authors have no conflicts of interest to declare.
Publisher Copyright:
© Translational Lung Cancer Research. All rights reserved.
PY - 2022/9
Y1 - 2022/9
N2 - Background: Topoisomerase is an essential enzyme for deoxyribonucleic acid replication, and its inhibitors suppress tumor progression. Amrubicin, a topoisomerase II inhibitor, is mainly used in the second-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). However, the impact of different types of topoisomerase inhibitors for first-line chemotherapy on the efficacy of amrubicin remains unclear. In the present study, we aimed to evaluate the efficacy of second-line amrubicin in patients with relapsed SCLC who were previously treated with platinum-based chemotherapy, including topoisomerase I and II inhibitors. Methods: This study retrospectively analyzed patients with ES-SCLC who experienced recurrence and were treated with amrubicin at 22 institutions in Japan between April 2015 and November 2020. The progression-free survival of amrubicin monotherapy was investigated using the Kaplan-Meier method. Results: A total of 320 patients were enrolled in this study, with 59 (18%) receiving platinum plus topoisomerase I inhibitor irinotecan and 261 (82%) receiving platinum plus topoisomerase II inhibitor etoposide as first-line treatment. The progression-free survival of amrubicin was significantly longer in the irinotecan group than in the etoposide group (3.2 vs. 2.5 months; P=0.034). Conclusions: These results showed that different types of topoisomerase inhibitors could affect the efficacy of amrubicin monotherapy in the second-line treatment of patients with relapsed ES-SCLC.
AB - Background: Topoisomerase is an essential enzyme for deoxyribonucleic acid replication, and its inhibitors suppress tumor progression. Amrubicin, a topoisomerase II inhibitor, is mainly used in the second-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). However, the impact of different types of topoisomerase inhibitors for first-line chemotherapy on the efficacy of amrubicin remains unclear. In the present study, we aimed to evaluate the efficacy of second-line amrubicin in patients with relapsed SCLC who were previously treated with platinum-based chemotherapy, including topoisomerase I and II inhibitors. Methods: This study retrospectively analyzed patients with ES-SCLC who experienced recurrence and were treated with amrubicin at 22 institutions in Japan between April 2015 and November 2020. The progression-free survival of amrubicin monotherapy was investigated using the Kaplan-Meier method. Results: A total of 320 patients were enrolled in this study, with 59 (18%) receiving platinum plus topoisomerase I inhibitor irinotecan and 261 (82%) receiving platinum plus topoisomerase II inhibitor etoposide as first-line treatment. The progression-free survival of amrubicin was significantly longer in the irinotecan group than in the etoposide group (3.2 vs. 2.5 months; P=0.034). Conclusions: These results showed that different types of topoisomerase inhibitors could affect the efficacy of amrubicin monotherapy in the second-line treatment of patients with relapsed ES-SCLC.
UR - http://www.scopus.com/inward/record.url?scp=85139875425&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139875425&partnerID=8YFLogxK
U2 - 10.21037/tlcr-22-160
DO - 10.21037/tlcr-22-160
M3 - Article
AN - SCOPUS:85139875425
SN - 2226-4477
VL - 11
SP - 1847
EP - 1857
JO - Translational Lung Cancer Research
JF - Translational Lung Cancer Research
IS - 9
ER -